istock-635475308-1-

CIPhotos / iStockphoto.com

15 February 2018Americas

BMS pays $1.85bn for immuno-oncology programme

Bristol-Myers Squibb (BMS) has agreed to pay $1.85 billion for an immuno-oncology programme.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More features

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic